Table 1.

Percentage of eyes with ≥ 2 levels of DRSS improvement in all eyes and highest-risk NPDR eyes at 3 and 12 months of the RISE/RIDE study. A significantly high proportion of eyes treated with ranibizumab had improvement of diabetic retinopathy by two levels or more by the DRSS scale than with sham injection. This was true for all eyes with diabetic retinopathy (p<0.001), but more so for the subset of eyes with the highest-risk NPDR at baseline. Thirty-two percent (32%) showed two or more levels of improvement after 3 months of treatment and 76% after 12 months of treatment, significantly higher than proportion of eyes receiving sham injection (0% at 3 months, 2% at 12 months, p<0.001).

	Sham injection	Ranibizumab, 0.3 mg	p-value
Month 3
All eyes	3%	18%	p<0.001
Highest-risk NPDR	0%	32%	p<0.001
Month 12
All eyes	3%	18%	p<0.001
Highest-risk NPDR	2%	76%	p<0.001

DRSS, diabetic retinopathy severity scale; NPDR, nonproliferative diabetic retinopathy.